Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4852W HIGH $2.64
Volume
2.79 M
Value Traded
5.34 M
Short % Float
2.9%
Days to Cover
1.0
-1.04%Week
+2.14%1 Month
+219.61%3 Month
+133.3%6 Month
-88.14%5 Year
-98.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
59.31 M
EPS (TTM)
-0.47
P/E Ratio
-
Ent. Value
54.56 M
Total Shares
31.05 M
Float Shares
27.14 M
Insiders
10.78%
Institutions
22.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
DRRX Catalyst Timeline
Dated clinical, regulatory and corporate events for DURECT Corporation
Past FDA Catalysts and PDUFA Decisions
How DRRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2018-08-06 | REMOXY ER (oxycodone extended-release) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DUR-928 Small moleculeCompletedNCT04563026 | Alcoholic Hepatitis | Phase 2 | COMPLETED | 326 | Sep 6, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every DRRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| larsucosterol BreakthroughFast Track | alcohol-associated hepatitis | Phase 2b | 2025-05-13 | 307 patients, approximately 100 patients in each armRead More | DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Farfel Gail MDirector | Option | 5,500 15,500 held | $1.22 | 09/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in DRRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 26.00 K | 26.39 K |
Ownership Trends
DRRX Short Interest
Shares sold short, counted twice a month.
2.9%
Short % of Float
of tradable shares sold short
345.0K
Shares Sold Short
-19.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
531.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DRRX ranks across every disease it competes in
Competitive Position is a premium feature
See how DRRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDRRX News
About DURECT Corporation
BIOPHARMAWATCH ELITE PLUS
Trade the next DRRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime